8-KShareholder Matters

ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (May 2, 2023)

Filed May 2, 2023For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on May 2, 2023, detailing the results of its Annual Meeting of Shareholders held on April 28, 2023. The report confirms the election of all nominated directors to the Board and the ratification of Ernst & Young LLP as the company's independent auditor. Shareholder approval was also given for the advisory vote on executive compensation and for holding this vote annually. Importantly, several shareholder proposals were voted down. These included proposals related to lowering the threshold for calling special meetings, requiring an independent board chairman, disclosing lobbying expenditures, and adjusting executive compensation metrics to exclude legal/compliance costs. The overwhelming support for the company's nominees and auditor, along with the rejection of these specific shareholder initiatives, signals continued confidence from the majority of shareholders in the current governance and operational strategies of Abbott Laboratories.

Key Highlights

  • 1All nominated directors were elected to the Abbott Laboratories Board of Directors.
  • 2Ernst & Young LLP was ratified as the company's independent auditor with substantial support.
  • 3Shareholders approved the advisory vote on the compensation of named executive officers, with 90.01% of votes cast in favor.
  • 4Shareholders overwhelmingly supported holding an annual advisory vote on executive compensation.
  • 5A shareholder proposal to lower the ownership threshold for calling special meetings was rejected.
  • 6Shareholder proposals concerning an independent board chairman, lobbying disclosure, and excluding legal costs from executive compensation adjustments were also rejected.

Frequently Asked Questions

The primary outcomes included the election of all nominated directors to the Board, the ratification of Ernst & Young LLP as auditors, and shareholder approval for the advisory vote on executive compensation, including the frequency of such votes (annually). Several shareholder-initiated proposals were also rejected.

Shareholders approved the compensation of Abbott's named executive officers with 90.01% of the votes cast voting 'For' the proposal. This vote is advisory and non-binding. Additionally, shareholders overwhelmingly voted to have this advisory vote on compensation conducted annually.

No, all shareholder-initiated proposals presented at the meeting were rejected by the shareholders. These proposals covered topics such as lowering the threshold for special meetings, requiring an independent board chairman, lobbying disclosure, and adjusting executive compensation metrics.

The election of all nominated directors and the ratification of the auditor indicate strong support from the majority of shareholders for the current leadership and governance structure of Abbott Laboratories. It suggests confidence in the company's management and oversight.